Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$25.13
+1.9%		$26.27
$19.16
▼
$48.25
$1.20B1.25603,561 shs547,889 shs
Bioventus Inc. stock logo
BVS
Bioventus
$12.98
-0.6%		$13.24
$6.26
▼
$15.89
$1.10B0.65535,958 shs421,805 shs
STAAR Surgical Company stock logo
STAA
STAAR Surgical
$22.66
-3.2%		$24.56
$15.59
▼
$35.87
$1.17B1.21810,035 shs838,686 shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.51
+3.7%		$4.49
$1.17
▼
$7.61
$282.90M1.4251,845 shs147,534 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+2.11%-1.81%-12.66%+25.40%-38.68%
Bioventus Inc. stock logo
BVS
Bioventus
-0.61%-7.75%-6.69%+52.53%+85.43%
STAAR Surgical Company stock logo
STAA
STAAR Surgical
-3.25%-3.45%-10.82%-20.13%-18.08%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
+3.68%-6.24%-5.05%+11.08%-35.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$25.13
+1.9%		$26.27
$19.16
▼
$48.25
$1.20B1.25603,561 shs547,889 shs
Bioventus Inc. stock logo
BVS
Bioventus
$12.98
-0.6%		$13.24
$6.26
▼
$15.89
$1.10B0.65535,958 shs421,805 shs
STAAR Surgical Company stock logo
STAA
STAAR Surgical
$22.66
-3.2%		$24.56
$15.59
▼
$35.87
$1.17B1.21810,035 shs838,686 shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.51
+3.7%		$4.49
$1.17
▼
$7.61
$282.90M1.4251,845 shs147,534 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
+2.11%-1.81%-12.66%+25.40%-38.68%
Bioventus Inc. stock logo
BVS
Bioventus
-0.61%-7.75%-6.69%+52.53%+85.43%
STAAR Surgical Company stock logo
STAA
STAAR Surgical
-3.25%-3.45%-10.82%-20.13%-18.08%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
+3.68%-6.24%-5.05%+11.08%-35.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
2.75
Moderate Buy$44.8378.42% Upside
Bioventus Inc. stock logo
BVS
Bioventus
2.83
Moderate Buy$16.8029.43% Upside
STAAR Surgical Company stock logo
STAA
STAAR Surgical
1.92
Reduce$28.4025.33% Upside
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
1.86
Reduce$5.1714.63% Upside

Current Analyst Ratings Breakdown

Latest TMCI, AORT, BVS, and STAA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/31/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/18/2026
Artivion, Inc. stock logo
AORT
Artivion
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$39.00 ➝ $40.00
8/17/2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$28.00
8/17/2026
Bioventus Inc. stock logo
BVS
Bioventus
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $19.00
8/17/2026
Bioventus Inc. stock logo
BVS
Bioventus
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$15.00
8/17/2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$31.00 ➝ $28.00
8/14/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$28.00
8/13/2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/13/2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$33.00
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$441.33M2.78$1.12 per share22.37$9.46 per share2.66
Bioventus Inc. stock logo
BVS
Bioventus
$568.09M1.92$1.27 per share10.24$2.76 per share4.70
STAAR Surgical Company stock logo
STAA
STAAR Surgical
$339.59M3.35N/AN/A$6.92 per share3.27
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$212.69M1.38N/AN/A$1.37 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
$9.77M-$0.07N/A32.63N/A-0.67%6.07%2.93%11/5/2026 (Estimated)
Bioventus Inc. stock logo
BVS
Bioventus
$22.73M$0.7716.8614.581.669.36%28.08%9.82%N/A
STAAR Surgical Company stock logo
STAA
STAAR Surgical
-$80.45M$0.07323.7641.96N/A1.13%9.05%6.99%11/4/2026 (Estimated)
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$59M-$0.93N/AN/AN/A-28.99%-71.37%-30.49%11/5/2026 (Estimated)

Latest TMCI, AORT, BVS, and STAA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
STAAR Surgical Company stock logo
STAA
STAAR Surgical
$0.2214$0.39+$0.1686$0.16$90.60 million$93.54 million
8/7/2026Q2 2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$0.2980-$0.24+$0.0580-$0.24$44.02 million$45.38 million
8/6/2026Q2 2026
Artivion, Inc. stock logo
AORT
Artivion
$0.0025$0.13+$0.1275-$0.28$119.99 million$125.76 million
8/5/2026Q2 2026
Bioventus Inc. stock logo
BVS
Bioventus
$0.22$0.22N/A$0.47N/A$153.21 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
STAAR Surgical Company stock logo
STAA
STAAR Surgical
N/AN/AN/AN/AN/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.82
3.47
2.51
Bioventus Inc. stock logo
BVS
Bioventus
0.83
1.69
1.17
STAAR Surgical Company stock logo
STAA
STAAR Surgical
N/A
4.66
4.03
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
0.83
2.90
1.95

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
STAAR Surgical Company stock logo
STAA
STAAR Surgical
96.70%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
84.08%

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
6.30%
Bioventus Inc. stock logo
BVS
Bioventus
33.50%
STAAR Surgical Company stock logo
STAA
STAAR Surgical
39.90%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
23.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,80048.76 million45.68 millionOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20084.09 million55.92 millionN/A
STAAR Surgical Company stock logo
STAA
STAAR Surgical
1,21150.14 million30.14 millionOptionable
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
25065.04 million49.80 millionOptionable

Recent News About These Companies

NexGel (NASDAQ:NXGL) vs. Treace Medical Concepts (NASDAQ:TMCI) Head-To-Head Survey
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31019070
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-position-in-treace-medical-concepts-inc-tmci-2026-09-06/
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-treace-medical-concepts-inc-nasdaq-tmci-given-consensus-recommendation-of-reduce-by-analysts-2026-09-05/
Bank of America Corp DE Has $4.31 Million Stock Holdings in Treace Medical Concepts, Inc. $TMCI
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-431-million-stock-holdings-in-treace-medical-concepts-inc-tmci-2026-08-29/
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 5,000 Shares
August 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tmci-insider-buying-and-selling-2026-08-25/
John Treace Acquires 5,000 Shares of Treace Medical Concepts (NASDAQ:TMCI) Stock
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-john-treace-acquires-5000-shares-of-treace-medical-concepts-nasdaq-tmci-stock-2026-08-24/
Insider Buying: Treace Medical Concepts (NASDAQ:TMCI) CEO Acquires 11,000 Shares
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-buying-treace-medical-concepts-nasdaq-tmci-ceo-acquires-11000-shares-2026-08-24/
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 39,944 Shares of Stock
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-treace-medical-concepts-nasdaq-tmci-ceo-john-treace-acquires-39944-shares-of-stock-2026-08-24/
Weber Capital Management LLC ADV Takes $2.35 Billion Position in Treace Medical Concepts, Inc. $TMCI
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-weber-capital-management-llc-adv-takes-235-billion-position-in-treace-medical-concepts-inc-tmci-2026-08-24/
Treace Medical Concepts Earnings Call Signals Cautious Rebound
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/treace-medical-concepts-earnings-call-signals-cautious-rebound?utm_source=marketbeat.com&utm_medium=referral
522,900 Shares in Treace Medical Concepts, Inc. $TMCI Purchased by Renaissance Technologies LLC
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-522900-shares-in-treace-medical-concepts-inc-tmci-purchased-by-renaissance-technologies-llc-2026-08-17/
Treace Medical (TMCI) Q2 2026 Earnings Call Transcript
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/treace-medical-tmci-q2-2026-135838195.html
Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary
August 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/treace-medical-concepts-inc-q2-211202340.html
Treace Medical Concepts: Q2 Earnings Snapshot
August 7, 2026  |  seattlepi.comS
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933135-treace-medical-concepts-inc-tmci-q2-2026-earnings-call-transcript
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970789/treace-medical-concepts-tmci-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970789
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341035/0/en/treace-medical-concepts-reports-second-quarter-2026-financial-results.html
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
July 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-treace-medical-concepts-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302834260.html
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332779/0/en/treace-to-report-second-quarter-2026-financial-results-on-august-7-2026.html
Why Treace Medical Concepts, Inc.’s (TMCI) Stock Is Down 5.42%
July 23, 2026  |  aaii.comA
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326260/0/en/Johnson-Fistel-PLLP-Investigates-Claims-on-Behalf-of-Long-Term-Shareholders-of-Treace-Medical-Concepts-Inc-TMCI.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$25.13 +0.48 (+1.94%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$25.08 -0.05 (-0.19%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Bioventus stock logo

Bioventus NASDAQ:BVS

$12.98 -0.08 (-0.61%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$12.88 -0.10 (-0.73%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

STAAR Surgical stock logo

STAAR Surgical NASDAQ:STAA

$22.66 -0.76 (-3.25%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$22.66 0.00 (-0.02%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Treace Medical Concepts stock logo

Treace Medical Concepts NASDAQ:TMCI

$4.51 +0.16 (+3.68%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.51 +0.00 (+0.11%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas